Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

Edgewise Therapeutics, Inc., a biopharmaceutical company, develops small molecule therapies for musculoskeletal diseases. The Company's lead product candidate, EDG-5506, is an orally administered small molecule designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy which has completed Phase 1 clinical trial. It develops a pipeline of precision medicine product candidates that target key muscle proteins and modulators to address genetically defined muscle disorders. Edgewise Therapeutics, Inc. was incorporated in 2017 and is headquartered in Boulder, Colorado.

Edgewise Therapeutics, Inc.

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

BOULDER, COLO. , SEPT. 3, 2025 /PRNEWSWIRE/ -- EDGEWISE THERAPEUTICS, INC. ("EDGEWISE" OR THE "COMPANY"), (NASDAQ: EWTX), A LEADING MUSCLE DISEASE BIOPHARMACEUTICAL COMPANY DEVELOPING NOVEL THERAPEUTICS FOR MUSCULAR DYSTROPHIES AND SERIOUS CARDIAC CONDITIONS, TODAY ANNOUNCED THAT ON AUGUST 29, 2025, EDGEWISE GRANTED INDUCEMENT STOCK OPTIONS TO PURCHASE A TOTAL OF 16,500 SHARES OF EDGEWISE'S COMMON STOCK TO 2 NEW NON-EXECUTIVE EMPLOYEES IN CONNECTION WITH THE COMMENCEMENT OF THEIR EMPLOYMENT, PURSUANT TO EDGEWISE'S 2024 INDUCEMENT EQUITY INCENTIVE PLAN (THE "INDUCEMENT PLAN").

EDGEWISE THERAPEUTICS REPORTS INDUCEMENT GRANTS AS PERMITTED BY THE NASDAQ LISTING RULES

NEW YORK, AUG. 17, 2025 (GLOBE NEWSWIRE) -- POMERANTZ LLP IS INVESTIGATING CLAIMS ON BEHALF OF INVESTORS OF EDGEWISE THERAPEUTICS, INC. (EDGEWISE OR THE COMPANY) (NASDAQ: EWTX). SUCH INVESTORS ARE ADVISED TO CONTACT DANIELLE PEYTON AT NEWACTION@POMLAW.COM OR 646-581-9980, EXT.7980.

INVESTOR ALERT: POMERANTZ LAW FIRM INVESTIGATES CLAIMSON BEHALF OF INVESTORS OF EDGEWISE THERAPEUTICS, INC. - EWTX

NEW YORK , AUG. 16, 2025 /PRNEWSWIRE/ --POMERANTZ LLP IS INVESTIGATING CLAIMS ON BEHALF OF INVESTORS OF EDGEWISE THERAPEUTICS, INC. ("EDGEWISE" OR THE "COMPANY") (NASDAQ: EWTX). SUCH INVESTORS ARE ADVISED TO CONTACT DANIELLE PEYTON ATNEWACTION@POMLAW.COMOR 646-581-9980, EXT.

INVESTOR ALERT: POMERANTZ LAW FIRM INVESTIGATES CLAIMS ON BEHALF OF INVESTORS OF EDGEWISE THERAPEUTICS, INC. - EWTX

INVESTORS CAN CONTACT THE LAW FIRM AT NO COST TO LEARN MORE ABOUT RECOVERING THEIR LOSSES

EDGEWISE THERAPEUTICS, INC. INVESTORS: COMPANY INVESTIGATED BY THE PORTNOY LAW FIRM

NEW YORK, AUG. 13, 2025 (GLOBE NEWSWIRE) -- POMERANTZ LLP IS INVESTIGATING CLAIMS ON BEHALF OF INVESTORS OF EDGEWISE THERAPEUTICS, INC. (EDGEWISE OR THE COMPANY) (NASDAQ: EWTX). SUCH INVESTORS ARE ADVISED TO CONTACT DANIELLE PEYTON AT NEWACTION@POMLAW.COM OR 646-581-9980, EXT.7980.

NEW YORK , AUG. 11, 2025 /PRNEWSWIRE/ -- POMERANTZ LLP IS INVESTIGATING CLAIMS ON BEHALF OF INVESTORS OF EDGEWISE THERAPEUTICS, INC. ("EDGEWISE" OR THE "COMPANY") (NASDAQ: EWTX). SUCH INVESTORS ARE ADVISED TO CONTACT DANIELLE PEYTON AT NEWACTION@POMLAW.COM OR 646-581-9980, EXT.

NEW YORK, AUG. 09, 2025 (GLOBE NEWSWIRE) -- POMERANTZ LLP IS INVESTIGATING CLAIMS ON BEHALF OF INVESTORS OF EDGEWISE THERAPEUTICS, INC. (EDGEWISE OR THE COMPANY) (NASDAQ: EWTX). SUCH INVESTORS ARE ADVISED TO CONTACT DANIELLE PEYTON AT NEWACTION@POMLAW.COM OR 646-581-9980, EXT.7980.

 ANNOUNCED POSITIVE TOP-LINE DATA FROM THE OPEN-LABEL EXTENSIONMESA TRIAL OF SEVASEMTEN IN PARTICIPANTS WITH BECKER MUSCULAR DYSTROPHY WHO PREVIOUSLY COMPLETED ARCH AND CANYON STUDIES   ANNOUNCED ENCOURAGING TOP-LINE DATA FROM THE PHASE 2 LYNX AND FOX TRIALS OF SEVASEMTEN IN DUCHENNE MUSCULAR DYSTROPHY   ADVANCED THE PHASE 2 CIRRUS-HCM TRIAL OF EDG-7500 IN HYPERTROPHIC CARDIOMYOPATHY (HCM)  BOULDER, COLO. , AUG. 7, 2025 /PRNEWSWIRE/ -- EDGEWISE THERAPEUTICS, INC., (NASDAQ: EWTX), A LEADING MUSCLE DISEASE BIOPHARMACEUTICAL COMPANY, TODAY REPORTED FINANCIAL RESULTS FOR THE SECOND QUARTER OF 2025 AND RECENT BUSINESS HIGHLIGHTS.

EDGEWISE THERAPEUTICS REPORTS SECOND QUARTER 2025 FINANCIAL RESULTS AND RECENT BUSINESS HIGHLIGHTS

BOULDER, COLO. , AUG. 6, 2025 /PRNEWSWIRE/ --EDGEWISE THERAPEUTICS, INC. ("EDGEWISE" OR THE "COMPANY"), (NASDAQ: EWTX), A LEADING MUSCLE DISEASE BIOPHARMACEUTICAL COMPANY DEVELOPING NOVEL THERAPEUTICS FOR MUSCULAR DYSTROPHIES AND SERIOUS CARDIAC CONDITIONS, TODAY ANNOUNCED THAT ON JULY 31, 2025, EDGEWISE GRANTED INDUCEMENT STOCK OPTIONS TO PURCHASE A TOTAL OF 84,250 SHARES OF EDGEWISE'S COMMON STOCK AND AWARDS OF INDUCEMENT RESTRICTED STOCK UNITS ("RSU AWARDS") COVERING A TOTAL OF 5,000 SHARES OF EDGEWISE'S COMMON STOCK TO 3 NEW NON-EXECUTIVE EMPLOYEES IN CONNECTION WITH THE COMMENCEMENT OF THEIR EMPLOYMENT, PURSUANT TO EDGEWISE'S 2024 INDUCEMENT EQUITY INCENTIVE PLAN (THE "INDUCEMENT PLAN").

NEW YORK , AUG. 6, 2025 /PRNEWSWIRE/ -- POMERANTZ LLP IS INVESTIGATING CLAIMS ON BEHALF OF INVESTORS OF EDGEWISE THERAPEUTICS, INC. ("EDGEWISE" OR THE "COMPANY") (NASDAQ: EWTX). SUCH INVESTORS ARE ADVISED TO CONTACT DANIELLE PEYTON AT NEWACTION@POMLAW.COM OR 646-581-9980, EXT.

NEW YORK , JULY 31, 2025 /PRNEWSWIRE/ -- POMERANTZ LLP IS INVESTIGATING CLAIMS ON BEHALF OF INVESTORS OF EDGEWISE THERAPEUTICS, INC. ("EDGEWISE" OR THE "COMPANY") (NASDAQ: EWTX). SUCH INVESTORS ARE ADVISED TO CONTACT DANIELLE PEYTON ATNEWACTION@POMLAW.COMOR 646-581-9980, EXT.

Edgewise Therapeutics, Inc.

EWTX

Price

Financials Overview

Financial Reports

No items found.

Press Releases

Edgewise Therapeutics, Inc.

EWTX.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financials Overview

Financial Reports

No items found.

Press Releases

EWTX